|
rs1801282
|
|
|
0.020 |
GeneticVariation |
BEFREE |
P12A PPARgamma did not significantly interact with BMI, WHR, energy intake, and energy expenditure to alter risk of colon or rectal cancer.
|
15860437 |
2005 |
|
rs1805192
|
|
|
0.020 |
GeneticVariation |
BEFREE |
P12A PPARgamma did not significantly interact with BMI, WHR, energy intake, and energy expenditure to alter risk of colon or rectal cancer.
|
15860437 |
2005 |
|
rs730881833
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A 39-year-old male patient with biallelic MYH mutations (p.G272E and p.A359V) received total proctocolectomy for rectal cancer and 36 colorectal polyps.
|
17703316 |
2007 |
|
rs35352891
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A 39-year-old male patient with biallelic MYH mutations (p.G272E and p.A359V) received total proctocolectomy for rectal cancer and 36 colorectal polyps.
|
17703316 |
2007 |
|
rs17026425
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A genome wide association study on Newfoundland colorectal cancer patients' survival outcomes.
|
25866641 |
2015 |
|
rs6854845
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A genome wide association study on Newfoundland colorectal cancer patients' survival outcomes.
|
25866641 |
2015 |
|
rs2632159
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A more pronounced effect was observed in the male subgroup in that <i>PCAT1</i> rs2632159 SNP increased rectal cancer risk by 3.97-fold (<i>P</i>=0.017).
|
31253700 |
2019 |
|
rs4939827
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A significant association of SNP in SMAD7 rs4939827 and CHI3L1 rs4950928 was revealed between the rectal cancer and colon cancer patients.
|
26779637 |
2016 |
|
rs4950928
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant association of SNP in SMAD7 rs4939827 and CHI3L1 rs4950928 was revealed between the rectal cancer and colon cancer patients.
|
26779637 |
2016 |
|
rs2269349
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A similar association of rs2269349 with rectal cancer was observed (OR=0.49; 95%CI=0.24-1.00).
|
24460263 |
2013 |
|
rs1801726
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, CASR SNP rs1801726 was significantly associated with a reduced risk for rectal cancer (OR = 0.53; 95% CI = 0.29-0.96).
|
20558521 |
2010 |
|
rs1061624
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, in rs1061624 of TNFRSF1B gene, AG genotype (OR=0.566; 95% CI= 0.362, 0.885) and AG/GG genotype (OR=0.638; 95% CI=0.420, 0.971) were significantly associated with a decreased risk of rectal cancer, respectively.
|
24762198 |
2014 |
|
rs7356
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After stratification for tumor location, the association of both SNPs was significant only for rectal cancer (rs7356: OR 1.52, 95% CI 1.02-2.26, P = 0.04 and rs4596: OR 0.69, 95% CI 0.50-0.94, P = 0.02; results not adjusted for multiple testing).
|
22581836 |
2012 |
|
rs4596
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After stratification for tumor location, the association of both SNPs was significant only for rectal cancer (rs7356: OR 1.52, 95% CI 1.02-2.26, P = 0.04 and rs4596: OR 0.69, 95% CI 0.50-0.94, P = 0.02; results not adjusted for multiple testing).
|
22581836 |
2012 |
|
rs397507444
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Although the MTHFR A1298C polymorphism was not associated with OS in CRC, this polymorphism was associated with significantly shorter OS in rectal cancer.
|
28044213 |
2017 |
|
rs4994
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Analysis of a subgroup with a higher body mass index showed that the Trp64Arg variant increased the OR (2.63; 95% confidence interval, 1.13-6.11) for colon cancer, but not for rectal cancer, compared with the Trp64 genotype.
|
11706779 |
2001 |
|
rs3802842
|
|
|
0.020 |
GeneticVariation |
BEFREE |
At 11q23.1, rs3802842 was significantly associated with rectal cancer risk only among African Americans (odds ratio, 1.34; P = .01); this observation was made in previous studies.
|
20659471 |
2010 |
|
rs2228545
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BMPR2 rs2228545 was associated with an almost twofold increased risk of rectal cancer.
|
21387313 |
2012 |
|
rs1800469
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both TGFβ1 rs1800469 and rs4803455 were associated with colon cancer [odds ratio (OR) = 0.65 and 1.43, 95% CI = 0.51-0.84 and 1.18-1.73, respectively) but not rectal cancer.
|
21068203 |
2011 |
|
rs4803455
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Both TGFβ1 rs1800469 and rs4803455 were associated with colon cancer [odds ratio (OR) = 0.65 and 1.43, 95% CI = 0.51-0.84 and 1.18-1.73, respectively) but not rectal cancer.
|
21068203 |
2011 |
|
rs1800925
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?
|
27167201 |
2016 |
|
rs4646903
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of the CYP1A1 rs4646903 CC homozygous variant showed a reduced risk of rectal cancer compared with that in TT carriers.
|
28273931 |
2017 |
|
rs712
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of the homozygous variant genotype TT for rs712 in KRAS gene were associated with a decreased risk of rectal cancer (odds ratio (OR) = 0.65, 95% confidence intervals (CI) 0.43-1.00, P = 0.05) while individuals with colon cancer carrying the heterozygous GT genotype showed a longer overall survival (OS) (P = 0.04).
|
29048575 |
2017 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 62.3% vs 51.6%, P=0.014; HR 1.43, CI 1.07-1.90, P=0.009), especially in rectal cancer (for DSS, HR: 10.60, CI: 3.04-36.92, P<0.001).
|
25973534 |
2015 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Compared with BRAF wild type, BRAF(V600E) was a risk for poor survival (overall survival; 5 years: 62.3% vs 51.6%, P=0.014; HR 1.43, CI 1.07-1.90, P=0.009), especially in rectal cancer (for DSS, HR: 10.60, CI: 3.04-36.92, P<0.001).
|
25973534 |
2015 |